<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934321</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201601141</org_study_id>
    <nct_id>NCT02934321</nct_id>
  </id_info>
  <brief_title>Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage</brief_title>
  <official_title>Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erythritol is a low calorie sugar substitute that is being increasingly used to sweeten&#xD;
      beverages and other food items. Greater amounts of erythritol are required to reach the&#xD;
      sweetness level of a common soft drink as compared to aspartame, resulting in higher&#xD;
      osmolarity for the erythritol sweetened beverage. Since associations have been noted between&#xD;
      osmolarity and satiety, investigators propose that an erythritol sweetened beverage may&#xD;
      enhance satiety more than a beverage sweetened with aspartame.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of an erythritol sweetened beverage on satiety has yet to be specifically&#xD;
      explored. In this double-blind, 2-way crossover trial, healthy volunteers will consume one of&#xD;
      two beverages on each visit: either an erythritol sweetened beverage or an aspartame&#xD;
      sweetened beverage. Both beverages will be prepared to the same level of sweetness.&#xD;
&#xD;
      Timed blood samples will be collected over a period of two hours following consumption of the&#xD;
      sweetened beverage. Serum total ghrelin and serum insulin will be measured from all blood&#xD;
      samples. A validated hunger scale will be administered three times within the two hour&#xD;
      period. Data analysis for all measures will be reported with respect to deviation from the&#xD;
      initial baseline measured at time 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Actual">August 23, 2019</completion_date>
  <primary_completion_date type="Actual">August 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ghrelin taken over 2 hours post beverage total area under curve (AUC)</measure>
    <time_frame>0 min, 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, 75 min, 90 min, 120 min following consumption of test drink</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ghrelin minimum concentration</measure>
    <time_frame>0 min, 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, 75 min, 90 min, 120 min following consumption of test drink</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>0 min, 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 60 min, 75 min, 90 min, 120 min following consumption of test drink</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hunger rating scale</measure>
    <time_frame>0 min, 30 min, 120 min following consumption of test drink</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Satiety in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Aspartame Sweetened Beverage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythritol Sweetened Beverage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Erythritol</intervention_name>
    <description>Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.</description>
    <arm_group_label>Erythritol Sweetened Beverage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aspartame</intervention_name>
    <description>Aspartame is a well tolerated, commonly used artificial sweetener.</description>
    <arm_group_label>Aspartame Sweetened Beverage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  BMI below 25&#xD;
&#xD;
          -  Maintained a stable body weight for at least three months prior to volunteering&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclude if smoking, substance abuse, have a chronic medical or psychiatric illness,&#xD;
             regularly intake medications (except for oral contraceptives), regularly use&#xD;
             supplements besides vitamins/minerals, have a history of gastrointestinal or renal&#xD;
             disorders, have food allergies, have medical dietary restrictions, or have any&#xD;
             abnormalities detected on physical examination indicative of disease.&#xD;
&#xD;
          -  Participants must have intact gastrointestinal and kidney function to adequately&#xD;
             absorb and eliminate the erythritol. Eligibility will be determined by self-reported&#xD;
             medical history, physical examination, and specific questioning to exclude prior renal&#xD;
             or Gastrointestinal disease after the informed consent process.&#xD;
&#xD;
          -  Exclude if abnormal GI anatomy due to surgery (besides appendix removal) or congenital&#xD;
             defect as may impair ghrelin production.&#xD;
&#xD;
          -  Exclude if the patient is pregnant, lactating, or planning to become pregnant as&#xD;
             erythritol has not been specifically tested in this population.&#xD;
&#xD;
          -  Exclude if have a Body Mass Index over 25, as ghrelin as a marker of satiety may not&#xD;
             be accurate at high Body Mass Index.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark L Brantly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythritol</keyword>
  <keyword>Satiety Response</keyword>
  <keyword>Ghrelin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythritol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

